- Home
- BRKR vs GH Comparison
BRKR vs GH Comparison
Compare BRKR & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRKR
- GH
- Stock Information
- Founded
- BRKR 1960
- GH 2011
- Country
- BRKR United States
- GH United States
- Employees
- BRKR 11396
- GH N/A
- Industry
- BRKR Biotechnology: Laboratory Analytical Instruments
- GH Medical Specialities
- Sector
- BRKR Industrials
- GH Health Care
- Exchange
- BRKR Nasdaq
- GH Nasdaq
- Market Cap
- BRKR 6.3B
- GH 4.9B
- IPO Year
- BRKR 2000
- GH 2018
- Fundamental
- Price
- BRKR $41.27
- GH $51.98
- Analyst Decision
- BRKR Buy
- GH Strong Buy
- Analyst Count
- BRKR 12
- GH 20
- Target Price
- BRKR $54.50
- GH $54.35
- AVG Volume (30 Days)
- BRKR 2.3M
- GH 2.3M
- Earning Date
- BRKR 08-05-2025
- GH 08-06-2025
- Dividend Yield
- BRKR 0.49%
- GH N/A
- EPS Growth
- BRKR N/A
- GH N/A
- EPS
- BRKR 0.52
- GH N/A
- Revenue
- BRKR $3,446,100,000.00
- GH $773,996,000.00
- Revenue This Year
- BRKR $6.43
- GH $23.14
- Revenue Next Year
- BRKR $4.21
- GH $21.42
- P/E Ratio
- BRKR $78.37
- GH N/A
- Revenue Growth
- BRKR 14.84
- GH 28.20
- 52 Week Low
- BRKR $34.10
- GH $20.14
- 52 Week High
- BRKR $72.94
- GH $53.42
- Technical
- Relative Strength Index (RSI)
- BRKR 63.98
- GH 63.61
- Support Level
- BRKR $37.55
- GH $47.45
- Resistance Level
- BRKR $39.16
- GH $51.15
- Average True Range (ATR)
- BRKR 1.69
- GH 2.29
- MACD
- BRKR 0.37
- GH 0.05
- Stochastic Oscillator
- BRKR 87.78
- GH 65.43
About BRKR Bruker Corporation
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.